NCT05574387View on ClinicalTrials.gov

Metformin as Added on Therapy in Patients With Ulcerative Colitis

PHASE2RecruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

January 20, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

April 30, 2027

Conditions
Inflammatory Bowel Diseases
Interventions
DRUG

Metformin

Metformin is an antidiabetic biguanide drug that acts by promoting glucose uptake and utilization in the liver.Recent studies proved that metformin could reduce colonic inflammation by AMPK-mediated inhibition of p38 mitogen-activated protein kinase (MAPK)

Trial Locations (1)

7650001

RECRUITING

Faculty of Medicine, Mansoura University, Al Mansurah

All Listed Sponsors
collaborator

Principal Investigator Mostafa Mahmoud Bahaa El-Dien Pharmacy Practice Department- Horus University

UNKNOWN

lead

Tanta University

OTHER